10-hydroxycamptothecin has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L | 1 |
| Chen, Z; Feng, Y; Guo, R; He, M; Hong, Z; Kong, X; Li, M; Li, Y; Tian, R; Wang, J; Wu, W; Yu, K; Yu, M | 1 |
2 other study(ies) available for 10-hydroxycamptothecin and Cancer of Prostate
| Article | Year |
|---|---|
Camptothecins in tumor homing via an RGD sequence mimetic.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats | 2012 |
A novel multifunctional poly(amidoamine) dendrimeric delivery system with superior encapsulation capacity for targeted delivery of the chemotherapy drug 10-hydroxycamptothecin.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chemistry, Pharmaceutical; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Endocytosis; Female; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Integrin alphaVbeta3; Kinetics; Male; MCF-7 Cells; Peptides, Cyclic; Polyamines; Prostatic Neoplasms; Solubility; Surface Properties; Technology, Pharmaceutical | 2014 |